Research programme: corticotropin releasing factor receptor antagonists - Neurocrine/GlaxoSmithKline
Alternative Names: NBI-35583; NBI-35965Latest Information Update: 24 Feb 2011
At a glance
- Originator Neurocrine Biosciences
- Developer GlaxoSmithKline; Neurocrine Biosciences
- Class Small molecules
- Mechanism of Action Corticotropin releasing factor receptor 1 antagonists; Corticotropin releasing factor receptor 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Irritable bowel syndrome; Major depressive disorder
Most Recent Events
- 19 Sep 2005 Data presented at the 230th American Chemical Society National Meeting (230th-ACS-2005) have been added to the Anxiety disorders pharmacodynamics section
- 19 May 2005 A preclinical study has been added to the Anxiety disorders pharmacodynamics section
- 12 Aug 2003 Preclinical trials in Anxiety disorders in USA (unspecified route)